Skip to main content Accessibility help
×
Hostname: page-component-7479d7b7d-qs9v7 Total loading time: 0 Render date: 2024-07-12T23:27:47.087Z Has data issue: false hasContentIssue false

130 - Selegiline

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Zelapar, Eldepryl, Emsam

Generic?

• Yes (as oral)

Class

• Antiparkinson agent

Commonly Prescribed for

(FDA approved in bold)

Parkinson's disease (PD)

Major depressive disorder, treatmentrefractory (patch only)

• Restless legs syndrome

• Anxiety disorders

• Alzheimer's and other dementias

• Migraine

How the Drug Works

• Selectively and irreversibly blocks monoamine oxidase type B (MAO-B) and increases extrastriatal extracellular dopamine levels. MAO-B is inhibited for at least 24 hours and the activity returns to baseline after 2 weeks. At higher doses, starts to affect MAO-A as well as MAO-B and inhibits metabolism of norepinephrine, serotonin, and tyramine, as well as dopamine

How Long Until It Works

• PD: weeks

• Depression, anxiety: usually months

If It Works

• PD: may require dose adjustments over time or augmentation with other agents. Most PD patients will eventually require carbidopa-levodopa to manage their symptoms

If It Doesn't Work

• Bradykinesia, gait, and tremor should improve. If the patient has significantly impaired functioning, add carbidopa-levodopa with or without a dopamine agonist

Best Augmenting Combos for Partial Response or Treatment-Resistance

• For suboptimal effectiveness, add carbidopa-levodopa with or without a catechol-O-methyl transferase (COMT) inhibitor or a dopamine agonist

• For younger patients with bothersome tremor: anticholinergics may help

• For severe motor fluctuations and/or dyskinesias with good “on” time, functional neurosurgery is an option

Tests

• Monitor for any changes in blood pressure

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Increases concentration of peripheral and CNS dopamine. At higher doses affects serotonin and norepinephrine levels

Notable AEs

• Nausea, hallucinations, confusion, lightheadedness, loss of balance, insomnia, orthostatic hypotension, hypertension, weight gain

Life-Threatening or Dangerous AEs

• Hypertensive crisis, especially at higher doses that prevent breakdown of tyramine (via MAO-A mostly). Tyramine-containing foods include aged cheeses, liver, sauerkraut, cured and processed meats, soy, alcohol (especially chianti wine and vermouth), and avocado

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 478 - 481
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Selegiline
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.131
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Selegiline
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.131
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Selegiline
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.131
Available formats
×